Dr. Khan is a Board Certified Psychiatrist and Adjunct Professor of Psychiatry at Duke University School of Medicine. He is the Medical Director and Principal Investigator at Northwest Clinical Research Center in Bellevue, Washington. Dr. Khan has been conducting clinical trials in the greater Seattle area since 1984 and founded NWCRC in 1995.

Dr. Khan has conducted over 90 clinical trials studying depression.  His research has been instrumental in the FDA approval of medication such as venlafaxine, paroxetine, citalopram, duloxetine and vilazadone, just to name a few.
A sample of Dr. Khan’s published works and features on depression are linked below.

Vedantam S.  Against depression a sugar pill is hard to beat. Washington Post: May 7th, 2002.
Click here to read this article.

Friedman RA.  Can the placebo treat depression? That depends.  New York Times: June 25th, 2002.
Click here to read this article.

Khan A, Khan S, Brown WA.  Are placebo controls necessary to test new antidepressants and anxiolytics?  International Journal of Neuropsychopharmacology 5: 193-197, 2002.
Click here to read this article.

Khan A, Kolts RL, Thase ME, Krishnan KR, Brown WA.  Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. American Journal of Psychiatry, 160(11): 2045-2049, 2004.
Click here to read this article.

Khan A, Warner H, Brown, WA.  Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the FDA database.  Archives of General Psychiatry 57: 311-317, 2000. 
Click here to read this article.

Dr. Kipp is a Board Certified primary care physician and has provided care to patients for over 30 years. He is currently a medical sub-investigator and has contributed to over 65 clinical trials here at NWCRC. When asked about his work, he says, “I enjoy patient contact and knowing that I’m making a difference through research.”